Skip to main content
. Author manuscript; available in PMC: 2009 Oct 19.
Published in final edited form as: Curr Protoc Immunol. 2001 May;CHAPTER:Unit–20.1. doi: 10.1002/0471142735.im2001s39

Table 20.1.3.

Troubleshooting Guide for Use of Mouse Model for Human Melanoma

Problem Possible cause Solution
Poor tumor take Mycoplasma infection of
tumor cultures
Eliminate mycoplasma with
ciprofloxacin or thaw vial
with fresh tumor sample
Overtrypsinization of tumor
cells
Dilute out trypsin with large
volume of HBSS as soon as
tumor cells dislodge; pellet
and discard supernatant
Tumor cells not kept on ice Keep tumor on ice at all time
Injected too few tumor cells Increase inoculum of tumor
cells
Poor treatment upon adoptive
transfer of CTL
Low potency or specificity of
CTL
Test CTL in vitro directly
prior to transfer to ensure
specificity
Too few CTL transferred Transfer more CTL, or
administer IL-2
Poor CTL growth Too little IL-2 in cultures Prepare new IL-2 stock, check
type of units
Poor FBS quality Test different FBS lots
“Dirty” cultures Purify on Ficoll to eliminate
debris
Over- or understimulation Restimulate every 7-10 days
Overcrowding of culture wells Split once CTL exceed 50%
confluency
Poor CTL specificity/high
background (often irreversible)
Too much IL-2 in cultures Keep [IL-2] between 30-60
IU/ml
“Dirty cultures” Ficoll to eliminate debris
Progressive deterioration of
specificity, large, granular,
fast-growing cells
Discard culture and thaw new
vial or establish new culture
from immunized mice
No induction of vitiligo
and/or antibodies upon two
immunizations with
rVVmTRP-1
Poor viral titer Retiter viral stock
Mixup of rVV stocks Check expression by
immunostaining of infected
cells